Prot# NLG-0201: A Phase II Study of HyperAcute®-Lung Cancer Vaccine in Subjects with Advanced Non-Small Cell Lung Cancer Who Responded to First Line Platinum-Doublet Treatment

Project: Research project

Project Details

StatusFinished
Effective start/end date2/21/079/1/11

Funding

  • NewLink Genetics Corporation (NLG-0201)